Scientists Gather to Discuss Novel Uses of Caliper Life Sciences’ Discovery Platforms and Technology

– Recent ‘Innovation for Experimentation’ Series Attracts Over 350 Attendees –

HOPKINTON, Mass., June 29 — Caliper Life Sciences, Inc. (Nasdaq: CALP – News), a leading provider of tools and services for drug discovery and life sciences research, reports that more than 350 customers recently attended its “Innovation for Experimentation” seminar series and open house events held in California and Massachusetts. The seminar series showcased how customers were successfully deploying technologies from Caliper to accelerate drug discovery research.

The events were held in San Francisco, San Diego and Hopkinton to discuss the importance of Caliper’s automation, microfluidics, and in vivo imaging technologies. Key themes included approaches for obtaining higher fidelity data that better predict human outcomes, increasing throughput and unattended run time while being cognizant of optimizing higher order workflows, decentralizing testing to ensure information is available in real time to decision makers, and increasing the knowledge generated per dollar, hour, and number of samples.

“The life sciences industry is tasked with the noble mission of finding cures and treatments for the sick and suffering,” said Kevin Hrusovsky, CEO of Caliper Life Sciences. “Our symposium series ‘Innovation for Experimentation’ enables us to better align our internal research priorities and investments with customer requirements to ensure that we develop technologies that enable our customers to be successful in increasing the quality and length of life. This year’s series was the best attended in years primarily due to our new comprehensive suite of ‘breakthrough’ LabChip, IVIS and Zephyr platforms.”

The events featured customer presentations focused on the adoption of Caliper platforms to accelerate discovery research at the following institutions: Pfizer, Merck, EMD Serono, Amgen, ArQule, Dana Farber Cancer Institute, Boehringer-Ingelheim, Wyeth, Calloway Labs, University of Massachusetts, Genencor, Bristol-Myers Squibb, XcellereX, SUNY Upstate, Vertex, Dow Biopharma, Symbiosis, MacroGenics, Geron, Elan, Roche, and the National Cancer Institute. The open house event in Hopkinton featured a keynote presentation from Kevin Hrusovsky, which is available online: https://www.caliperls.com/investors/open-house-061909-ceo-presentation.php.

Investors and analysts were also invited to attend and participate in a separate breakout session featuring presentations by Kevin Hrusovsky, President and CEO, as well as several members of Caliper’s executive team, who outlined Caliper’s strategic priorities and the future direction of Caliper’s technologies and services. A webcast of this breakout session is available online: https://phx.corporate-ir.net/phoenix.zhtml?c=85833&p=irol-EventDetails&EventId=2268770.

About Caliper Life Sciences

Caliper Life Sciences is a premier provider of cutting-edge technologies enabling researchers in the life sciences industry to create life-saving and enhancing medicines and diagnostic tests more quickly and efficiently. Caliper is aggressively innovating new technology to bridge the gap between in vitro assays and in vivo results and then translating those results into cures for human disease. Caliper’s portfolio of offerings includes state-of-the-art microfluidics, lab automation & liquid handling, optical imaging technologies, and discovery & development outsourcing solutions. For more information please visit www.caliperLS.com.

Caliper, LabChip, IVIS, and Zephyr are registered trademarks of Caliper Life Sciences, Inc.

Copyright © 2009 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.